Learn more about Eli Lilly and Company's Revenue by Segment and Revenue by Region.
Check out competitors to Eli Lilly and Company in a side-by-side comparison.
Explore additional financial metrics for Eli Lilly and Company.
| 2015 | 19958700000.00 |
|---|---|
| 2016 | 21222100000.00 |
| 2017 | 19973800000.00 |
| 2018 | 21493300000.00 |
| 2019 | 22319500000.00 |
| 2020 | 24539800000.00 |
| 2021 | 28318400000.00 |
| 2022 | 28541400000.00 |
| 2023 | 34124100000.00 |
| 2024 | 45042700000.00 |
| 2025 | 65179000000.00 |
| Mar 2016 | 4865100000.00 |
|---|---|
| Jun 2016 | 5404800000.00 |
| Sep 2016 | 5191700000.00 |
| Dec 2016 | 5760500000.00 |
| Mar 2017 | 5228300000.00 |
| Jun 2017 | 5824300000.00 |
| Sep 2017 | 5658000000.00 |
| Dec 2017 | 6160700000.00 |
| Mar 2018 | 4963800000.00 |
| Jun 2018 | 5585000000.00 |
| Sep 2018 | 5306900000.00 |
| Dec 2018 | 6438600000.00 |
| Mar 2019 | 5092200000.00 |
| Jun 2019 | 5636700000.00 |
| Sep 2019 | 5476600000.00 |
| Dec 2019 | 6114000000.00 |
| Mar 2020 | 5859800000.00 |
| Jun 2020 | 5499400000.00 |
| Sep 2020 | 5740600000.00 |
| Dec 2020 | 7440000000.00 |
| Mar 2021 | 6805600000.00 |
| Jun 2021 | 6740100000.00 |
| Sep 2021 | 6772800000.00 |
| Dec 2021 | 7999900000.00 |
| Mar 2022 | 7810000000.00 |
| Jun 2022 | 6488000000.00 |
| Sep 2022 | 6941600000.00 |
| Dec 2022 | 7301800000.00 |
| Mar 2023 | 6960000000.00 |
| Jun 2023 | 8312100000.00 |
| Sep 2023 | 9498600000.00 |
| Dec 2023 | 9353400000.00 |
| Mar 2024 | 8768000000.00 |
| Jun 2024 | 11302800000.00 |
| Sep 2024 | 11439100000.00 |
| Dec 2024 | 13532800000.00 |
| Mar 2025 | 12728500000.00 |
| Jun 2025 | 15557700000.00 |
| Sep 2025 | 17600800000.00 |
| Dec 2025 | 19292000000.00 |
| Mar 2026 | 19799000000.00 |
Eli Lilly and Company's annual revenue was $65.18 B in fiscal year 2025.
Eli Lilly and Company's quarterly revenue was $12.73 B(Q1: Mar 2025), $15.56 B(Q2: Jun 2025), $17.60 B(Q3: Sep 2025), $19.29 B(Q4: Dec 2025) in fiscal year 2025.
Eli Lilly and Company's annual revenue was $45.04 B in fiscal year 2024.
Eli Lilly and Company's quarterly revenue was $8.77 B(Q1: Mar 2024), $11.30 B(Q2: Jun 2024), $11.44 B(Q3: Sep 2024), $13.53 B(Q4: Dec 2024) in fiscal year 2024.
Eli Lilly and Company's annual revenue was $34.12 B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $6.96 B(Q1: Mar 2023), $8.31 B(Q2: Jun 2023), $9.50 B(Q3: Sep 2023), $9.35 B(Q4: Dec 2023) in fiscal year 2023.
Eli Lilly and Company's annual revenue was $28.54 B in fiscal year 2022.
Eli Lilly and Company's quarterly revenue was $7.81 B(Q1: Mar 2022), $6.49 B(Q2: Jun 2022), $6.94 B(Q3: Sep 2022), $7.30 B(Q4: Dec 2022) in fiscal year 2022.
Eli Lilly and Company's annual revenue was $28.32 B in fiscal year 2021.
Eli Lilly and Company's quarterly revenue was $6.81 B(Q1: Mar 2021), $6.74 B(Q2: Jun 2021), $6.77 B(Q3: Sep 2021), $8.00 B(Q4: Dec 2021) in fiscal year 2021.
Eli Lilly and Company's annual revenue was $24.54 B in fiscal year 2020.
Eli Lilly and Company's quarterly revenue was $5.86 B(Q1: Mar 2020), $5.50 B(Q2: Jun 2020), $5.74 B(Q3: Sep 2020), $7.44 B(Q4: Dec 2020) in fiscal year 2020.
Eli Lilly and Company's annual revenue was $22.32 B in fiscal year 2019.
Eli Lilly and Company's quarterly revenue was $5.09 B(Q1: Mar 2019), $5.64 B(Q2: Jun 2019), $5.48 B(Q3: Sep 2019), $6.11 B(Q4: Dec 2019) in fiscal year 2019.
Eli Lilly and Company's annual revenue was $21.49 B in fiscal year 2018.
Eli Lilly and Company's quarterly revenue was $4.96 B(Q1: Mar 2018), $5.59 B(Q2: Jun 2018), $5.31 B(Q3: Sep 2018), $6.44 B(Q4: Dec 2018) in fiscal year 2018.
Eli Lilly and Company's annual revenue was $19.97 B in fiscal year 2017.
Eli Lilly and Company's quarterly revenue was $5.23 B(Q1: Mar 2017), $5.82 B(Q2: Jun 2017), $5.66 B(Q3: Sep 2017), $6.16 B(Q4: Dec 2017) in fiscal year 2017.
Eli Lilly and Company's annual revenue was $21.22 B in fiscal year 2016.
Eli Lilly and Company's quarterly revenue was $4.87 B(Q1: Mar 2016), $5.40 B(Q2: Jun 2016), $5.19 B(Q3: Sep 2016), $5.76 B(Q4: Dec 2016) in fiscal year 2016.
| 2015 | 0 |
|---|---|
| 2016 | +6.33 |
| 2017 | -5.88 |
| 2018 | +7.61 |
| 2019 | +3.84 |
| 2020 | +9.95 |
| 2021 | +15.40 |
| 2022 | +0.79 |
| 2023 | +19.56 |
| 2024 | +32.00 |
| 2025 | +44.70 |
| Q1: Mar 16 | 4.75 |
|---|---|
| Q2: Jun 16 | 8.56 |
| Q3: Sep 16 | 4.68 |
| Q4: Dec 16 | 7.16 |
| Q1: Mar 17 | 7.47 |
| Q2: Jun 17 | 7.76 |
| Q3: Sep 17 | 8.98 |
| Q4: Dec 17 | 6.95 |
| Q1: Mar 18 | -5.06 |
| Q2: Jun 18 | -4.11 |
| Q3: Sep 18 | -6.21 |
| Q4: Dec 18 | 4.51 |
| Q1: Mar 19 | 2.59 |
| Q2: Jun 19 | 0.93 |
| Q3: Sep 19 | 3.20 |
| Q4: Dec 19 | -5.04 |
| Q1: Mar 20 | 15.07 |
| Q2: Jun 20 | -2.44 |
| Q3: Sep 20 | 4.82 |
| Q4: Dec 20 | 21.69 |
| Q1: Mar 21 | 16.14 |
| Q2: Jun 21 | 22.56 |
| Q3: Sep 21 | 17.98 |
| Q4: Dec 21 | 7.53 |
| Q1: Mar 22 | 14.76 |
| Q2: Jun 22 | -3.74 |
| Q3: Sep 22 | 2.49 |
| Q4: Dec 22 | -8.73 |
| Q1: Mar 23 | -10.88 |
| Q2: Jun 23 | 28.11 |
| Q3: Sep 23 | 36.84 |
| Q4: Dec 23 | 28.10 |
| Q1: Mar 24 | 25.98 |
| Q2: Jun 24 | 35.98 |
| Q3: Sep 24 | 20.43 |
| Q4: Dec 24 | 44.68 |
| Q1: Mar 25 | 45.17 |
| Q2: Jun 25 | 37.64 |
| Q3: Sep 25 | 53.87 |
| Q4: Dec 25 | 42.56 |
| Q1: Mar 26 | 55.55 |
Eli Lilly and Company’s annual revenue increased +44.70% during fiscal year 2025 compared to 2024. It represents a growth of $20.14 B from $45.04 B (in 2024) to $65.18 B (in 2025).
Eli Lilly and Company’s annual revenue increased +32.00% during fiscal year 2024 compared to 2023. It represents a growth of $10.92 B from $34.12 B (in 2023) to $45.04 B (in 2024).
Eli Lilly and Company’s annual revenue increased +19.56% during fiscal year 2023 compared to 2022. It represents a growth of $5.58 B from $28.54 B (in 2022) to $34.12 B (in 2023).
Eli Lilly and Company’s annual revenue increased +0.79% during fiscal year 2022 compared to 2021. It represents a growth of $223.00 M from $28.32 B (in 2021) to $28.54 B (in 2022).
Eli Lilly and Company’s annual revenue increased +15.40% during fiscal year 2021 compared to 2020. It represents a growth of $3.78 B from $24.54 B (in 2020) to $28.32 B (in 2021).
Eli Lilly and Company’s annual revenue increased +9.95% during fiscal year 2020 compared to 2019. It represents a growth of $2.22 B from $22.32 B (in 2019) to $24.54 B (in 2020).
Eli Lilly and Company’s annual revenue increased +3.84% during fiscal year 2019 compared to 2018. It represents a growth of $826.20 M from $21.49 B (in 2018) to $22.32 B (in 2019).
Eli Lilly and Company’s annual revenue increased +7.61% during fiscal year 2018 compared to 2017. It represents a growth of $1.52 B from $19.97 B (in 2017) to $21.49 B (in 2018).
Eli Lilly and Company’s annual revenue decreased -5.88% during fiscal year 2017 compared to 2016. It represents a decline of $1.25 B from $21.22 B (in 2016) to $19.97 B (in 2017).
Eli Lilly and Company’s annual revenue increased +6.33% during fiscal year 2016 compared to 2015. It represents a growth of $1.26 B from $19.96 B (in 2015) to $21.22 B (in 2016).
Sign in to download table
| Period | Revenue | Year-over-Year Change |
|---|---|---|
|
Get instant access to data, Sign up for free
FY 2025
|
$65.18 B |
$20.14 B
|
| Q4: Dec 25 | $19.29 B |
$5.76 B
|
| Q3: Sep 25 | $17.60 B |
$6.16 B
|
| Q2: Jun 25 | $15.56 B |
$4.25 B
|
| Q1: Mar 25 | $12.73 B |
$3.96 B
|
|
Get instant access to data, Sign up for free
FY 2024
|
$45.04 B |
$10.92 B
|
| Q4: Dec 24 | $13.53 B |
$4.18 B
|
| Q3: Sep 24 | $11.44 B |
$1.94 B
|
| Q2: Jun 24 | $11.30 B |
$2.99 B
|
| Q1: Mar 24 | $8.77 B |
$1.81 B
|
|
Get instant access to data, Sign up for free
FY 2023
|
$34.12 B |
$5.58 B
|
| Q4: Dec 23 | $9.35 B |
$2.05 B
|
| Q3: Sep 23 | $9.50 B |
$2.56 B
|
| Q2: Jun 23 | $8.31 B |
$1.82 B
|
| Q1: Mar 23 | $6.96 B |
-$850.00 M
|
|
Get instant access to data, Sign up for free
FY 2022
|
$28.54 B |
$223.00 M
|
| Q4: Dec 22 | $7.30 B |
-$698.10 M
|
| Q3: Sep 22 | $6.94 B |
$168.80 M
|
| Q2: Jun 22 | $6.49 B |
-$252.10 M
|
| Q1: Mar 22 | $7.81 B |
$1.00 B
|
|
Get instant access to data, Sign up for free
FY 2021
|
$28.32 B |
$3.78 B
|
| Q4: Dec 21 | $8.00 B |
$559.90 M
|
| Q3: Sep 21 | $6.77 B |
$1.03 B
|
| Q2: Jun 21 | $6.74 B |
$1.24 B
|
| Q1: Mar 21 | $6.81 B |
$945.80 M
|
|
Get instant access to data, Sign up for free
FY 2020
|
$24.54 B |
$2.22 B
|
| Q4: Dec 20 | $7.44 B |
$1.33 B
|
| Q3: Sep 20 | $5.74 B |
$264.00 M
|
| Q2: Jun 20 | $5.50 B |
-$137.30 M
|
| Q1: Mar 20 | $5.86 B |
$767.60 M
|
|
Get instant access to data, Sign up for free
FY 2019
|
$22.32 B |
$826.20 M
|
| Q4: Dec 19 | $6.11 B |
-$324.60 M
|
| Q3: Sep 19 | $5.48 B |
$169.70 M
|
| Q2: Jun 19 | $5.64 B |
$51.70 M
|
| Q1: Mar 19 | $5.09 B |
$128.40 M
|
|
Get instant access to data, Sign up for free
FY 2018
|
$21.49 B |
$1.52 B
|
| Q4: Dec 18 | $6.44 B |
$277.90 M
|
| Q3: Sep 18 | $5.31 B |
-$351.10 M
|
| Q2: Jun 18 | $5.59 B |
-$239.30 M
|
| Q1: Mar 18 | $4.96 B |
-$264.50 M
|
|
Get instant access to data, Sign up for free
FY 2017
|
$19.97 B |
-$1.25 B
|
| Q4: Dec 17 | $6.16 B |
$400.20 M
|
| Q3: Sep 17 | $5.66 B |
$466.30 M
|
| Q2: Jun 17 | $5.82 B |
$419.50 M
|
| Q1: Mar 17 | $5.23 B |
$363.20 M
|
|
Get instant access to data, Sign up for free
FY 2016
|
$21.22 B |
$1.26 B
|
| Q4: Dec 16 | $5.76 B |
$384.90 M
|
| Q3: Sep 16 | $5.19 B |
$232.00 M
|
| Q2: Jun 16 | $5.40 B |
$426.10 M
|
| Q1: Mar 16 | $4.87 B |
$220.40 M
|
In fiscal year 2025, Eli Lilly and Company's revenue was $65.18 Billion.
Eli Lilly and Company's revenue increased by +44.70% (+$20.14 Billion) in 2025 compared to 2024.
In the first quarter (Q1) of 2026, Eli Lilly and Company reported a revenue of $19.80 Billion.
Eli Lilly and Company's revenue per share over the trailing twelve months is $80.77.
In the fiscal year 2025, Eli Lilly and Company's revenue per employee was $1.30 Million.
In fiscal year 2025, Eli Lilly and Company's net income was $20.64 Billion.
Product is Eli Lilly and Company's biggest product segment, generating $60.96 Billion in revenue for fiscal year 2025.
In the fiscal year 2025, Eli Lilly and Company's net income per employee was $412.77 K.